Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Latigo Biotherapeutics, a private drug company developing experimental pain medicines, has closed another ...

THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million for drugs that it hopes will challenge Vertex ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs. The round was led by Blue Owl Capital, with other ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...